SV2A PET is a promising research biomarker for biological characterization of synucleinopathies, however, the field remains limited by small cohorts, methodological heterogeneity, variable quantification strategies, limited longitudinal evidence, and potential cohort overlap.
This systematic analysis of SV2A PET studies across all brain disorders shows SD loss across disorders with disease-specific patterns, consistent with postmortem and genetic findings and regionally selective synaptic alterations within disorders point to circuit-level vulnerability rather than uniform global synaptic l...
G. Mirfallah, C. Schifani, D. Shateri et al.· International Journal of Neu...· 0 citations
Although the field remains limited by small cohorts, heterogeneous quantification strategies, and incomplete longitudinal validation, SV2A PET is rapidly evolving into a promising translational tool for studying synaptopathies and monitoring disease progression.
L. Filippi, S. Nuvoli, A. Spanu et al.· Molecular Diagnosis & Therap...· 0 citations
The biomarker and therapeutic potential of STX1A remains preliminary because diagnostic performance, disease specificity, longitudinal stability, and causal relevance have not been adequately validated and future studies using cell-type-specific STX1A manipulation, rescue experiments, electrophysiology, and multicenter...
Rui Xu, Rui Li, Hong-Mei Li et al.· Frontiers in Aging Neuroscie...· 0 citations
Current evidence supports neuroinflammation imaging primarily for mechanistic investigation, patient stratification, and trial enrichment rather than routine clinical deployment, and should therefore be interpreted as a collection of target-specific, stage-dependent biological readouts rather than as a unitary measure...
This review summarizes motor system degeneration in aging and disease, focusing on the primary motor cortex (M1), its white matter tracts, and the nigrostriatal system.
OBJECTIVE
Scans Without Evidence of Dopaminergic Deficit (SWEDD) refers to individuals with Parkinsonian symptoms but no presynaptic dopaminergic deficit on dopamine transporter (DAT) imaging. Given its likely heterogeneity, we used a multimodal imaging approach to compare SWEDD with Parkinson's disease (PD) and health...
Faranak Ebrahimian Sadabad, Tommaso Volpi, Sule Tinaz et al.· Parkinsonism & Related Disor...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
